10X Genomics Inc

Healthcare · Health Information Services

80.70$ +4.4% vs. previous close Closing price · As of: Oct 9, 2026

Statements

Balance Sheet

10X Genomics Inc (TXG) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 1,030 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size %

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet TXG
Line item	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Total Assets	–	–	124	124	0.0	156	573	606	610	583	1,043	929	954	978	991	1,019	1,003	1,002	996	1,029	1,014	990	949	965	923	930	938	919	903	980	1,027	1,041	1,016	1,030
Current Assets	48	–	106	106	65	107	474	481	430	452	900	774	746	757	744	748	697	666	629	635	602	583	562	596	567	579	594	584	580	656	660	684	670	675
Cash	-48	–	65	65	-65	56	427	424	372	340	769	664	617	622	600	587	312	274	234	220	332	326	311	359	356	380	398	344	377	398	433	474	490	503
Cash & Short-Term Investments	48	–	0.0	65	65	56	427	424	372	340	769	664	617	622	600	587	539	500	452	430	418	391	357	389	372	380	398	393	427	447	482	523	540	552
Receivables	–	–	30	28	0.0	35	26	33	31	23	36	51	57	60	78	85	77	76	84	104	78	88	104	115	91	91	84	88	53	119	97	82	56	51
Inventory	–	–	8.6	8.6	0.0	12	13	15	19	22	25	30	39	44	51	60	64	71	79	82	82	84	81	74	83	88	94	83	75	69	62	56	53	53
Property, Plant & Equipment	–	–	11	11	0.0	38	47	49	96	99	110	73	107	176	203	230	190	296	258	289	292	285	354	–	–	–	–	–	–	–	–	–	–	–
Goodwill	–	–	0.0	0.0	0.0	0.0	–	–	–	–	–	–	4.5	4.5	4.5	4.5	4.5	4.5	4.5	4.5	4.5	4.5	4.5	4.5	4.5	4.5	4.5	4.5	4.5	4.5	4.5	4.5	4.5	6.9
Intangible Assets	–	–	0.4	0.4	0.0	0.4	–	22	–	22	22	22	27	27	26	25	25	24	23	23	23	22	22	17	16	17	16	16	15	15	65	62	60	61
Total Liabilities	–	–	101	344	0.0	140	151	186	201	192	217	190	202	193	190	201	197	218	220	223	212	196	203	224	204	206	215	209	196	207	242	245	201	205
Current Liabilities	–	–	32	32	0.0	43	48	63	59	122	146	118	121	113	100	110	94	118	127	131	112	98	105	127	109	111	121	118	108	112	147	153	114	119
Short-Term Debt	–	–	0.0	4.2	0.0	4.9	7.4	9.9	3.5	3.9	5.0	5.9	6.2	4.9	4.5	5.1	7.6	8.0	8.4	9.0	9.2	9.3	10	12	11	11	9.4	9.3	9.4	9.7	11	11	11	12
Accounts Payable	–	–	8.8	8.8	0.0	9.4	12	13	14	9.9	9.5	4.7	16	16	17	17	19	27	22	22	29	23	19	16	20	21	26	13	10	16	18	13	17	21
Long-Term Debt	–	–	25	25	0.0	25	22	20	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Shareholders' Equity	46	–	-220	-220	23	15	421	420	409	391	825	739	752	785	800	818	807	784	776	806	802	793	745	741	719	724	723	710	707	773	785	796	814	826
Retained Earnings	–	–	-231	-231	0.0	-246	-255	-262	-284	-324	-390	-805	-817	-828	-845	-863	-906	-970	-1,012	-1,029	-1,080	-1,142	-1,235	-1,284	-1,344	-1,382	-1,418	-1,467	-1,501	-1,467	-1,494	-1,511	-1,524	-1,542
Shares Outstanding	78	78	14	14	15	16	88	96	97	99	101	107	109	110	111	112	113	114	114	115	116	117	118	119	119	120	121	122	123	125	126	127	128	130

Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Balance Sheet

Cookie settings